Brian Lawler said in this article that Thailand is making a mistake in allowing either the manufacture or importation of generic versions of Abbott's HIV treatment Kaletra and Sanofi-Aventis' blood clot drug Plavix, even though the drugs are still under patent protection and producing generic versions would be illegal in many countries. The annual health care cost savings would amount to just $24 million per year, but would greatly damage the perception of how the country treats intellectual property rights and patents, Lawler said.
The Motley Fool
The Motley Fool